Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP14 | P50281 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.41 |
| ▸ | GPR3 | P46089 | 2/20 | 0.39 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL80634 | 0.93 | TRPV1 (0.58) | TRPV1EPHX2MAPTGPR3L3MBTL1 | |
| SCHEMBL28780452 | 0.88 | EPHX2 (0.50) | EPHX2FAAHMAPTMMP2MMP9 | |
| SCHEMBL254957 | 0.80 | MAPT (0.56) | TRPV1EPHX2MAPTGPR3L3MBTL1 | |
| SCHEMBL3841043 | 0.80 | LTA4H (0.50) | MAPTMMP2MMP9LTA4H | |
| SCHEMBL3845620 | 0.80 | LTA4H (0.50) | MAPTMMP2MMP9LTA4H | |
| SCHEMBL2883028 | 0.80 | LTA4H (0.50) | MAPTMMP2MMP9LTA4H | |
| SCHEMBL3671300 | 0.79 | APP (0.40) | TRPV1MAPTMMP2MMP9LTA4H | |
| SCHEMBL7937983 | 0.79 | GPR3 (0.47) | EPHX2FAAHMAPTMMP2MMP9 | |
| SCHEMBL3306191 | 0.79 | LTA4H (0.57) | EPHX2FAAHMAPTSLC6A2SLC6A4 | |
| SCHEMBL1584629 | 0.78 | SLC6A2 (0.46) | TRPV1EPHX2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| EP-3293184-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2020-12-16 | — | — | EP | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2020-09-15 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2019-01-03 | — | — | US | disclosed |
| US-10059675-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-2964639-B1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9163008-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163008-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-10-20 | — | — | US | disclosed |
| US-9163008-B2 | Pyrimidines as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-10-20 | — | — | US | disclosed |
| EP-2871180-A1 | 2-AMINONICOTINIC ACID ESTER DERIVATIVE AND BACTERICIDE CONTAINING SAME AS ACTIVE INGREDIENT | Agro-Kanesho Co., Ltd. (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2014-10-09 | — | — | US | disclosed |
| WO-2014135955-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135955-A1 | PYRIMIDINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-09-12 | — | — | WO | disclosed |
| WO-2013030665-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196364-B2 | Pyrimidine carboxamides as sodium channel blockers | CACNA1A, TRPV1, TRPA1 | TRPV1 2/4885EPHX2 1187/4885FAAH 440/4885 |
| US-10059675-B2 | Pyrimidines as sodium channel blockers | P2RX3, CACNA1A, P2RX4 | TRPV1 17/4885EPHX2 504/4885FAAH 1149/4885 |
| US-20190002412-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX3, CACNA1A, P2RX4 | TRPV1 17/4885EPHX2 504/4885FAAH 1149/4885 |
| US-10774050-B2 | Pyrimidines as sodium channel blockers | P2RX3, CACNA1A, P2RX4 | TRPV1 17/4885EPHX2 504/4885FAAH 1149/4885 |
| US-20140303139-A1 | PYRIMIDINES AS SODIUM CHANNEL BLOCKERS | P2RX1, P2RX4, P2RX2 | TRPV1 16/4885EPHX2 535/4885FAAH 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.